Prevention challenges: The era of atherosclerosis regression

Canadian Journal of Cardiology

Volumn 22, Issue SUPPL. C, 2006, Pages 27C-30C

  Tardif, Jean Claude ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Atherosclerosis: Cholesteryl ester transfer protein; HDL cholesterol; Intravascular ultrasound

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; ATORVASTATIN; AVASIMIBE; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; ETC 216; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PACTIMIBE; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TORCETRAPIB;

AGING; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DIABETES MELLITUS; DISEASE COURSE; DISEASE MODEL; DRUG EFFICACY; DRUG INFUSION; DRUG MECHANISM; FOLLOW UP; HEART PROTECTION; HUMAN; LIFESTYLE; METABOLIC SYNDROME X; MONOTHERAPY; NONHUMAN;

EID: 33845630285     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0828-282x(06)70999-0     Document Type: Conference Paper

References (36)

1. Castelli WP. Lipids, risk factors and ischaemic heart disease. Atherosclerosis 1996;124(Suppl):S1-S9.
2. Jensen LO, Thayssen P, Pedersen KE, Stender S, Haghfelt T. Regression of coronary atherosclerosis by simvastatin: A serial intravascular ultrasound study. Circulation 2004;110:265-70.
3. Tardif JC, Grégoire J, L'Allier PL, et al; Avasimibe and Progression of Lesions on UltraSound (A-PLUS) Investigators. Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation 2004;110:3372-7.
4. Nissen SE, Tuzcu EM, Brewer HB, et al; ACAT Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Investigators. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med 2006;354:1253-63.
5. Nissen SE, Tuzcu EM, Schoenhagen P, et al; REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 2004;291:1071-80.
6. Nissen SE, Nicholls SJ, Sipahi I, et al; ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA 2006;295:1556-65.
7. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
8. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
9. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
10. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
11. Cannon CP, Braunwald E, McCabe CH, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504. (Erratum in 2006;354:778).
12. LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.
13. Pedersen TR, Faergeman O, Kastelein JJ, et al; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial. JAMA 2005;294:2437-45. (Erratum in 2005;294:3092).
14. Tardif JC, Grégoire J, Lespérance J, et al. Design features of the Avasimibe and Progression of coronary Lesions assessed by intravascular UltraSound (A-PLUS) clinical trial. Am Heart J 2002; 144:589-96.
15. Heinonen TM. Inhibition of acyl coenzyme A-cholesterol acyltransferase: A possible treatment of atherosclerosis. Curr Atheroscler Rep 2002;4:65-70.
16. Fazio S, Major AS, Swift LL, et al. Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages. J Clin Invest 2001;107:163-71.
17. Alsheikh-Ali AA, Kuvin JT, Karas RH. High-density lipoprotein cholesterol in the cardiovascular equation: Does the "good" still count? Atherosclerosis 2005;180:217-23.
18. Calabresi L, Gomaraschi M, Franceschini G. Endothelial protection by high-density lipoproteins: From bench to bedside. Arterioscler Thromb Vasc Biol 2003;23:1724-31.
19. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res 2004;95:764-72.
20. Shah PK, Yano J, Reyes O, et al. High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization. Circulation 2001;103:3047-50.
21. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA 2003;290:2292-300.
22. de Grooth GJ, Klerkx AH, Stroes ES, Stalenhoef AF, Kastelein JJ, Kuivenhoven JA. A review of CETP and its relation to atherosclerosis. J Lipid Res 2004;45:1967-74.
23. Clark RW, Sutfin TA, Ruggeri RB, et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: An initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 2004;24:490-7.
24. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: A novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23:160-7.
25. Morehouse LA, Sugarman ED, Bourassa PA, Milici AJ. HDL elevation by the CETP-inhibitor torcetrapib prevents aortic atherosclerosis in rabbits. Circulation 2004:1168. (Abst)
26. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004;350:1505-15.
27. Kastelein JJP, Bois ML, Riley WA, et al. Design of a study comparing torcetrapib/atorvastatin with atorvastatin alone on carotid atherosclerosis in patients with familial hypercholesterolemia. The 75th European Atherosclerosis Society Congress. Prague, April 23 to 26, 2005.
28. Bots ML, Riley WA, Evans GW, et al. Design of a study on the effect of torcetrapib/atorvastatin versus atorvastatin alone on carotid intima-media thickness in patients with mixed hyperlipidemia. The 75th European Atherosclerosis Society Congress. Prague, April 23 to 26, 2005.
29. Nissen SE, Tardif JC, Crowe T, et al. Design of a study comparing torcetrapib/atorvastatin with atorvastatin alone on atheroma volume in patients with coronary heart disease. The 75th European Atherosclerosis Society Congress. Prague, April 23 to 26, 2005.
30. Tardif JC, Grégoire J, Schwartz L, et al; Canadian Antioxidant Restenosis Trial (CART-1) Investigators. Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation 2003;107:552-8.
31. De Caterina R, Zampolli A. From asthma to atherosclerosis - 5-lipoxygenase, leukotrienes, and inflammation. N Engl J Med 2004;350:4-7.
32. 2 predict coronary events in patients with coronary artery disease Circulation 1999;100:1280-4.
33. Dai E, Viswanathan K, Sun YM, et al. Identification of myxomaviral serpin reactive site loop sequences that regulate innate immune responses. J Biol Chem 2006;281:8041-50.
34. Yanovski SZ. Pharmacotherapy for obesity - Promise and uncertainty. N Engl J Med 2005;353:2187-9.
35. Nigam A, Bourassa MG, Fortier A, Guertin MC, Tardif JC. The metabolic syndrome and its components and the long-term risk of death in patients with coronary heart disease. Am Heart J 2006;151:514-21.
36. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: Final report of the Lyon Diet Heart Study. Circulation 1999;99:779-85.